Skip to main content
. 2017 Aug 31;124(1):1–9. doi: 10.1152/japplphysiol.00455.2016

Table 3.

Summary of muscle mass or LBM estimates

First Dosing Occasion
Repeat Dosing Occasion
N n Mean SD N n Mean SD
D3-creatine
    Method 1 (urine)
     HV female 4 4 16.94 1.111 3 3 15.64 0.347
     HV male 10 10 26.47 3.494 10 10 27.74 4.029
     CHF male 2 2 26.82 5.007 1 1 35.37
     COPD male 2 2 28.00 0.688
    Method 2 (urine)
     HV female 4 4 16.31 1.245 3 3 14.71 0.802
     HV male 10 10 25.98 3.581 10 10 27.14 3.510
     CHF male 2 2 25.99 5.279 1 1 32.48
     COPD male 2 2 26.70 0.002
    Method 3 (urine)
     HV female 4 4 16.09 1.201 3 3 14.98 0.313
     HV male 10 10 26.07 3.027 10 10 27.12 4.068
     CHF male 2 2 27.79 8.576 1 1 30.00
     COPD male 2 2 26.48 0.211
    Method 4 (plasma)
     HV female 4 2 18.95 0.584 3 3 19.42 0.777
     HV male 10 10 31.83 3.879 10 4 32.26 4.817
     CHF male 2 2 27.48 6.832 1 1 28.99
     COPD male 2 2 26.42 0.189
MRI
     HV female 4 4 18.41 1.897 3 3 17.22 0.701
     HV male 10 10 30.24 4.719 10 10 29.77 4.753
     CHF male 2 1 23.24
     COPD male 2 2 25.43 0.988
DXA
    Total LBM
     HV female 4 4 36.39 2.674 3 3 35.88 1.576
     HV male 10 10 54.61 7.285 10 10 54.03 7.418
     CHF male 2 2 49.96 4.562 1 1 52.26
     COPD male 2 2 47.07 0.350
    ALM
     HV female 4 4 15.84 1.570 3 3 15.27 1.091
     HV male 10 10 24.85 3.871 10 10 24.77 4.110
     CHF male 2 2 21.86 3.569 1 1 22.99
     COPD male 2 2 20.21 0.264
24-h UCrn (mean of 3 days)
     HV female 4 4 12.43 1.470 3 3 12.97 1.234
     HV male 10 10 20.62 3.216 10 10 22.03 3.366
     CHF male 2 2 15.23 3.496 1 1 14.60
     COPD male 2 2 20.10 1.399

Values are expressed in kg. LBM, lean body mass; N, total group size; n, number of subjects who provided data used to calculate mean; ALM, appendicular lean mass; SD, standard deviation; MRI, magnetic resonance imaging; DXA, dual-energy X-ray absorptiometry; 24-h UCrn; 24-h urinary creatinine excretion.